Business
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer.
About this update from Scopus Biopharma, Inc.
[{"type":"text","content":"\n NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS”), a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is developing novel immunotherapies to overcome treatment-resistant cancers, today announced that Marcin Kortylewski, Ph.D., Co-Founder and Senior Scientific Advisor of Duet and Professor of Immuno-Oncology at City of Hope, will be presenting at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”). SITC is being held from November 3-5, 2023, in San Diego, California. Details of the presentation are as follows: Title: Reprograming of Tumor-associated Myeloid Cells by TLR9-targeted STAT3 Antisense Oligonucleotides Sensitizes Malignant Glioma to PD1-specific ImmunotherapyPresentation Type: PosterPresenter: Marcin Kortylewski, Ph.D., Duet BioTherapeutics; City of HopeSession: Poster ReceptionPoster Board Number: 812Session Date/Time: Saturday, November 4, 2023, 7:00 PM – 8:30 PM PDT About Scopus BioPharma Scopus BioPharma Inc. is a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need. Scopus currently conducts substantially all of its development efforts through Duet BioTherapeutics, its majority owned and controlled subsidiary. The Company is also seeking to identify additional compelling technologies for potential acquisition, in-licensing and/or other similar transactions. About Duet BioTherapeutics Duet BioTherapeutics Inc. is a biotechnology company developing novel immunotherapies to overcome treatment-resistant cancers. Duet’s therapeutic candidates selectively and simultaneously activate TLR9, which stimulates the body’s immune system, and inhibit STAT3, which counteracts critical tumor defense mechanisms. Duet is currently pursuing therapeutic candidates for the treatment of solid tumors and hematological malignancies using a distinct set of oligonucleotide inhibitors. These inhibitors include antisense, or ASO; small-interfering RNA, or siRNA; and decoy technologies. DUET-101, the Company’s IND-ready lead candidate, combines CpG with a STAT3-inhibiting ASO and is being developed for the treatment of advanced solid tumors. Forward-...